|Awarded On||February 21, 2019|
|Title||Lymphatic Delivery of Checkpoint Blockade Inhibitors for More Effective Immunotherapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Eva M Sevick|
*Pending contract negotiation
Tumor draining lymphatics and regional the lymph nodes play important roles in cancer metastases and cancer immunotherapies. In patients with locally advanced cancers, “naïve” T-cells within the tumor draining LNs are prevented from becoming “educated” to attack cancer by a series of “checkpoints”. Therapeutics to block these checkpoints are typically given intravenously -- which is an ineffective means to maximize drug in the tumor draining LNs. While effective, a dangerous side effect of these i.v. administered therapeutics is that the entire immune system can become overstimulated, attacking normal tissues as well as tumors. In fact, the immune-related adverse effects (irAEs) can be s...